Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral mucositis: the hidden side of cancer therapy.
Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Pulito C, et al. Among authors: porta c. J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. doi: 10.1186/s13046-020-01715-7. J Exp Clin Cancer Res. 2020. PMID: 33028357 Free PMC article. Review.
Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel.
Quaquarini E, D'Ambrosio D, Sottotetti F, Gallivanone F, Hodolic M, Baiardi P, Palumbo R, Vellani C, Canevari C, Bernardo A, Castiglioni I, Porta C, Trifirò G. Quaquarini E, et al. Among authors: porta c. Contrast Media Mol Imaging. 2019 Mar 26;2019:4325946. doi: 10.1155/2019/4325946. eCollection 2019. Contrast Media Mol Imaging. 2019. PMID: 31049043 Free PMC article.
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
Manzini VP, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M. Manzini VP, et al. Among authors: porta c. Ann Oncol. 2010 Feb;21(2):348-353. doi: 10.1093/annonc/mdp307. Epub 2009 Jul 27. Ann Oncol. 2010. PMID: 19635740 Free article.
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Powles T, Albiges L, Bex A, Comperat E, Grünwald V, Kanesvaran R, Kitamura H, McKay R, Porta C, Procopio G, Schmidinger M, Suarez C, Teoh J, de Velasco G, Young M, Gillessen S; ESMO Guidelines Committee. Powles T, et al. Among authors: porta c. Ann Oncol. 2024 May 20:S0923-7534(24)00676-8. doi: 10.1016/j.annonc.2024.05.537. Online ahead of print. Ann Oncol. 2024. PMID: 38788900 No abstract available.
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.
Borghesani M, Reni A, Lauricella E, Rossi A, Moscarda V, Trevisani E, Torresan I, Al-Toubah T, Filoni E, Luchini C, De Robertis R, Landoni L, Scarpa A, Porta C, Milella M, Strosberg J, Cives M, Cingarlini S. Borghesani M, et al. Among authors: porta c. J Natl Compr Canc Netw. 2024 May 14:1-8. doi: 10.6004/jnccn.2024.7005. Online ahead of print. J Natl Compr Canc Netw. 2024. PMID: 38744314
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, Grande E, De Giorgi U, Molina-Cerrillo J, Seront E, Calabrò F, Myint ZW, Facchini G, Kopp RM, Berardi R, Kucharz J, Vitale MG, Pinto A, Formisano L, Büttner T, Messina C, Monteiro FSM, Battelli N, Kanesvaran R, Büchler T, Kopecký J, Santini D, Giudice GC, Porta C, Santoni M. Fiala O, et al. Among authors: porta c. Target Oncol. 2024 May 5. doi: 10.1007/s11523-024-01065-w. Online ahead of print. Target Oncol. 2024. PMID: 38704759
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, George S, Scheffold C, Wang P, Fedorov V, Motzer RJ, Choueiri TK. Powles T, et al. Among authors: porta c. ESMO Open. 2024 May;9(5):102994. doi: 10.1016/j.esmoop.2024.102994. Epub 2024 Apr 20. ESMO Open. 2024. PMID: 38642472 Free PMC article. Clinical Trial.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J. Massari F, et al. Among authors: porta c. Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w. Cancer Immunol Immunother. 2024. PMID: 38634928 Free PMC article.
955 results